CuratisAG
Contact Us
Investor Relations

Financial News

Ad-hoc announcements pursuant to Art. 53 LR and corporate news releases from Curatis Holding AG.

Ad-hoc Releases

DateHeadline
May 22, 2026Curatis Holding AG announces CHF 3.0 million private placement with strategic investorPDF
Mar 24, 2026Curatis: Double-digit revenue growth in 2025 and major milestones for corticorelin achievedPDF
Mar 11, 2026Curatis and Neupharma announce exclusive licensing agreement to develop and market corticorelin (C-PTBE-01) for the treatment of peritumoral brain edema in JapanPDF
Nov 21, 2025Curatis Holding AG announces CHF 1.2 million private placement with strategic investorPDF
Sep 15, 2025Curatis: Double-digit growth in core business and development milestone achieved for C-PTBE-01PDF
May 23, 2025Curatis discloses Corticorelin as active substance of C-PTBE-01 | Market Opportunity in PTBE expected to exceed USD 1 billionPDF

Corporate News

DateHeadline
May 22, 2026Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors
Sep 18, 2025FDA minutes confirm positive outcome of meeting on 9 September 2025 — Corticorelin on track for Phase 3
Sep 5, 2025Curatis expands distribution business with Phoenix Labs with up to CHF 5m additional annual revenues
Jul 31, 2025FDA Confirms Type B Meeting on Corticorelin Pivotal Phase 3 Study
May 24, 2025Annual General Meeting of Curatis Holding AG approved all proposals of the Board of Directors
Mar 11, 2025Curatis Announces Formation of Distinguished Advisory Board
Jul 25, 2024Curatis Holding AG: Initiation of Coverage and Publication of Equity Research Report by VALUATIONLAB